Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma.

Abatacept was found to be safe and effective for jLS subjects refractory to standard of care treatment. Subjects experienced improvement in both skin and musculoskeletal activity. Prospective studies should be performed to more fully evaluate abatacept's efficacy.